Lung Injury Articles & Analysis
16 news found
Recent advances in the fight against severe acute inflammatory lung diseases, including COVID-19, have revealed a promising new approach to treating pulmonary hyperinflammation and long-term lung damage such as fibrosis. A groundbreaking study has developed a first-in-class, carbohydrate-coupled inhibitor of microRNA-21 (RCS-21), which shows significant potential as a therapeutic agent. This ...
Currently, some researchers have focused on the effects of dexmedetomidine pretreatment on lipopolysaccharide-induced acute lung injury in mice, while others have focused on the impact of primary neonatal rat cardiomyocytes under hypoxic/reoxygenation conditions using dexmedetomidine hydrochloride. ...
The second study (the “DLCO Study”) will measure the effects of TSC on the ability of the lungs to transfer gas from inspired air to the bloodstream, using carbon monoxide as a surrogate for oxygen. The DLCO Study will be conducted in patients with previously diagnosed interstitial lung disease. Diffusion plans to commence the DLCO Study in the second ...
ByCervoMed
However, ECMO does not remove the circulating inflammatory cytokines and other toxins that can contribute to ongoing injury to the lungs and other vital organs and prevent or delay healing. ...
These adult and pediatric patients have chronic respiratory insufficiency due to conditions such as high spinal cord injuries (SCI), Congenital Hypoventilation Syndrome (CCHS), Central Sleep Apnea, Acute Flaccid Myelitis (AFM), various central neurological disorders, autoimmune diseases including Multiple Sclerosis and diseases caused by insect bites like Lyme Disease. For those ...
” Researchers noted that these patients experienced quicker extubation, less lung trauma and less oxygen toxicity. Stemedica went on to receive U.S. FDA approval for a Phase Ila clinical trial for patients with moderate to severe lung injury due to COVID-19 or other potential viral and bacterial pathogens. ...
Lung Therapeutics LTI-03 uniquely inhibits both fibroblast activation and promotes the survival and function of alveolar epithelial cell subtypes needed for lung regeneration in IPF. ...
Published in this month’s Experimental Physiology, the study, entitled, “Temporal changes in pulmonary gas exchange efficiency when breath-hold diving below residual volume,” demonstrated that breath-hold diving to depths associated with major lung compression, or “lung squeeze,” caused acute impairments in pulmonary gas exchange. ...
The FDA has issued an EUA for the Hemolung RAS to treat lung failure caused by COVID-19. As indicated in the FDA’s EUA letter to ALung, the Hemolung RAS is not FDA-cleared or approved, and there are no FDA-approved or cleared device treatments for lung failure caused by COVID-19. ...
To date, Lung Therapeutics has raised a total of $53 million in outside funding. ...
The main challenge is to place and position the tube correctly in the GI tract, avoiding the lungs. Current insertion methodologies are limited and it is estimated that 1 million tubes are misplaced annually worldwide. Misplacement of the tube in the lungs can cause signi?cant patient injury, including death, and lead to prolonged hospital stay ...
tiakis BIOTECH AG today announced the publication of research results by Alcazar et al. from Stanford University on a new mechanism by which Elafin rescues lung cell survival in the lung of newborn mice subjected to mechanical ventilation. Neonatal chronic lung disease or bronchopulmonary dysplasia develops in preterm infants whose ...
Lung Therapeutics, Inc., a clinical stage pharmaceutical company developing novel therapeutics for niche, orphan drug indications in fibrosis, lung injury and disease, announced today the successful completion of a $14.3 million Series B financing. The proceeds will support ongoing LTI-01 clinical trials in Australia and New Zealand, as well as ...
Intended to replace costly surgery and ineffective off-label treatments of fibrosis, the drug can provide safer and more cost-effective therapeutic options for CPE/empyema patients and healthcare providers worldwide. Lung Therapeutics, Inc., a clinical stage pharmaceutical company focused on niche, orphan drug indications in lung injury and ...
In fact, the oil giant had merely covered up the poisonous pond with four feet of dirt and a thin layer of grass… all this is part of the massive environmental damage and accompanying cancer clusters, lung disease, skin lesions and other injuries left behind by a U.S. multinational corporation." ...
Feinberg, the administrator of the 9/11 compensation fund, says that approximately 11,000 people who have filed lawsuits attempting to claim compensation for injuries would have been covered by the compensation fund if their symptoms had appeared before December 2003. Many of these people are suffering lung injuries and illnesses caused by ...